Delivers the widest range of APIs in a transdermal format scalable to your needs
The 3M Microstructured Transdermal Systems (MTS) microneedle platform combines the efficiency of a syringe with the convenience of a transdermal device to expand the range of transdermally deliverable drugs.
Local or systemic delivery for both large and difficult to deliver molecules, including proteins, peptides and vaccines
Improves delivery efficiency and absorption time of some drugs and vaccines
Potential for dose sparing – important for high-value biologics
Capability to enhance stability for some drugs
Available in a solid or hollow design to meet the needs of your program
3M Hollow Microneedle System
Hollow channels allow efficient transdermal delivery of liquid formulations
With up to 2mL capacity, the 3M Hollow Microstructured Transdermal System (hMTS) is a wearable hollow microneedle device designed for efficient delivery of liquid formulations.
3M Solid Microneedle System
Transdermal delivery with efficiency that matches or exceeds that provided by injection
With up to 0.3 mg capacity, the 3M Solid Microstructured Transdermal System (sMTS) is a small, wearable state-of-the-art microneedle device for transdermal delivery of highly potent proteins or vaccines.
Let 3M experts demonstrate how MTS technology can meet your needs. Contact us for more information.
Delivery of human growth hormone by hMTS shows an earlier Tmax and a higher Cmax than is achieved by subcutaneous administration in a swine model.
Delivery of polyclonal antibody (57 mg/mL with dextrose and buffer) using hMTS shows systemic bioavailability and PK profile similar to subcutaneous administration in a swine model.
Study of ovalbumin using sMTS demonstrates short wear time required for effective intradermal release in a swine model.
Model Virus-like Protein (VLP) immunogenicity study demonstrates dose-sparing potential for sMTS delivery of vaccines.